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c-MYB and TGFb: EMT’s dynamic duo in breast cancer
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c-MyB is the prototype member of a small fam-
ily of transcription factors that include B-MyB 
and A-MyB, involved in cell survival, prolifera-
tion, differentiation and transformation.1
c-MyB has been studied extensively in 
the hematopietic system, where it plays an 
important role in the maintenance and dif-
ferentiation of stem cells, explaining its fre-
quent deregulation in leukemias.2 Recent 
evidence corroborates the hypothesis that a 
key function of c-MyB is to control stem cells 
in different tissues, and it is thought to exert its 
physiological and cancer-promoting functions 
by transactivating key target genes involved in 
cell growth, self-renewal and anti-apoptosis.1,3
A recent study by the group of Giuseppe 
Raschellá has established that c-MyB activates 
epithelial-to-mesenchymal transition (eMT) in 
human cancer cells of different origin by trans-
activating sLUG.4 sLUG is a developmentally 
regulated gene important for specification 
of the neural crest, aberrantly expressed in 
aggressive, metastatic forms of cancer. Other 
groups have independently demonstrated 
that c-MyB activity is required for eMT in the 
neural crest and the development of sLUG-
expressing neural crest structures in lower ver-
tebrates, suggesting that regulation of eMT by 
c-MyB occurs in different patho-physiological 
settings and is evolutionary conserved.5,6
in a new study published in the December 
1st issue of Cell Cycle, Raschellá and coworkers 
show that c-MyB is a TGFb-regulated gene in 
estrogen receptor-positive (eR+) mammary 
cancer cells. Using different approaches, they 
demonstrate that c-MyB is upregulated by 
TGFb, at least in part by suppression of the 
miR200 network. “seed” sequences belonging 
to members of miR200 family are identified in 
the 3′ untranslated region of c-MyB and are 
shown to be essential for miR downregulation. 
in the presence of TGFb, the miR200 mem-
bers are inactivated, resulting in stabilization 
of c-MyB. notably, the expression of BCL2 
and sLUG evoked by TGFb is blunted after 
silencing c-MyB in breast cancer cell lines. The 
authors conclude that c-MyB is a new TGFb 
target gene, explaining how mechanistically 
TGFb promotes eMT in breast cancer cells.
A limitation of the study is that it has been 
conducted with cell lines in vitro, so it will be 
important to corroborate the findings in mouse 
models of breast cancer and in the context of 
primary human tissues. notwithstanding this 
limitation, the paper is consistent with recent 
investigations from the Ramsay and Gonda 
laboratories, also suggesting that c-MyB has 
a promoting role in eR+ breast cancer.1 This 
unified picture is somewhat complicated by 
other studies in which the expression of c-MyB 
has been associated with very good prog-
nosis in breast cancer.7 Furthermore, c-MyB 
transcriptionally activates Hep27, resulting in 
attenuation of Mdm2 and stabilization of p53 
in eR+ breast cancer cells.8 To explain these 
contradictory results, one could hypothesize 
that the phenotypic outcome of c-MyB acti-
vation in breast cancer cells depends on sig-
nals from the microenvironment. For example, 
TGFb is produced by stromal myofibroblasts 
to support breast cancer progression.9 in this 
context, c-MyB could promote a more aggres-
sive tumor phenotype by activating sLUG. in 
other circumstances, c-MyB expression could 
be beneficial to patients’ prognosis by sup-
porting the function of p53, thus imparting a 
more benign phenotype to breast cancer cells. 
whatever the case may be, the new study from 
the Raschellá group further brings c-MyB at 
the center stage of eMT signaling and breast 
cancer, reiterating the fundamental impor-
tance of this oncoprotein in development and 
disease.
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Aging is a highly complex, multifactorial pro-
cess. evidence collected over the last two 
decades has nonetheless vividly demonstrated 
that specific genetic mutations can extend 
lifespan, and that the pathways involved are 
highly conserved across wide evolutionary 
distances.1,2 The nutrient-sensing target of 
rapamycin (TOR) pathway plays a key role 
in cellular growth and metabolism and is a 
highly conserved modulator of aging.2-4 At 
the core of this pathway lies the TOR kinase, 
which forms the catalytic subunit of two 
distinct complexes; TOR complex 1 (TORC1) 
and TORC2.4 TOR primarily mediates its meta-
bolic effects through the phosphorylation of 
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downstream effectors such as s6 kinase 1 
(s6K1) and eiF4e-binding protein1 (4e-BP1).2,4 
Critically, the TOR pathway is also highly acces-
sible to pharmacological intervention, with 
rapamycin specifically inhibiting the ability of 
TORC1 to phosphorylate its downstream effec-
tors. Rapamycin treatment has been shown 
to increase lifespan in yeast, Drosophila and 
genetically heterogeneous mice,5-8 to aug-
ment stress resistance in Drosophila2 and 
to delay and/or reduce pathology in several 
mouse models of disease.4 These findings have 
pushed rapamycin and associated rapalogs to 
the forefront of candidate drugs that could 
ultimately be capable of improving health dur-
ing aging in humans.
in the December 15th issue of Cell Cycle, 
a study by Anisimov and colleagues dem-
onstrates that lifelong rapamycin treatment 
extends the lifespan of inbred female 129/sv 
mice.9 notably, the drug improved survival to 
extreme older ages, with 31% of the rapamy-
cin treated group but only 10% of the con-
trol group alive at 900 d of age. importantly, 
this research shows that rapamycin’s positive 
effects on lifespan appear consistent across 
different genetic backgrounds in mice, with 
the earlier work undertaken using hetero-
geneous (UM-HeT3) mice6,7 or cancer-prone 
HeR-2/neu mice.8 These data are reassuring, 
given that genetic background can profoundly 
influence the effect of a particular intervention 
on lifespan.10,11 in addition, it is crucial that the 
effects on lifespan of particular pharmaco-
logical agents are consistent across different 
mouse strains if they are eventually to be clini-
cally tested.7 The study also demonstrated that, 
irrespective of how rapamycin is delivered, be 
it via diet6,7 or via subcutaneous injection (this 
study), the beneficial effects on lifespan are 
demonstrable. interestingly, in the study by 
Anisimov et al., the rapamycin was injected 
three times weekly only every second fort-
night, indicating that intermittent treatment 
is sufficient to increase adult lifespan. it has 
been suggested that one possible drawback 
of early-life treatment with rapamycin is that it 
could potentially affect growth during critical 
developmental stages. However, rapamycin 
treatment in this study was initiated from 
2 mo of age with no apparent effect on growth 
during development, although the rapamycin 
treated mice were significantly lighter later in 
life, associated with a reduction in food intake. 
There could also have been metabolic effects 
on body weight, because a previous study 
reported that rapamycin retarded an age-
related decline in spontaneous activity, but 
only in male mice.6
Another striking finding was that signifi-
cantly fewer of the rapamycin-treated mice 
had tumors (specifically uterine tumors) com-
pared with control mice despite the incidence 
of chromosomal aberrations in bone marrow 
cells being significantly higher at 26 mo of age. 
These findings contrast with other studies,6,7 
where comprehensive pathological investiga-
tion indicated that rapamycin did not alter the 
presumed cause of death. The reason for this 
discrepancy is unclear, but one could certainly 
speculate that life-long supplementation is 
necessary to induce this anticancer effect. 
Again, it is remarkable that this effect on 
tumorigenesis was observed despite rapamy-
cin being administered only intermittently. A 
detailed study of the effects of rapamycin on 
the incidence and timing of different types of 
tumor would seem warranted.
This work raises several important ques-
tions regarding rapamycin and its impact on 
lifespan and health. First, it is critical to now 
determine exactly what causes of death are 
ameliorated by rapamycin to extend lifes-
pan, beyond the implicated effects on cancer. 
second, interventions that increase lifespan 
are often sex-specific in their effects, and, 
indeed, rapamycin seems to increase lifes-
pan more in female mice7 and Drosophila5 
compared with males. A comparable study of 
effects of rapamycin on lifespan and causes 
of death in male mice is needed. Third, as 
the authors themselves suggest, it is now 
critical to determine whether later-life rapamy-
cin treatment (e.g., 9 or 20 mo) using this 
same protocol for delivery of the drug has 
as great an effect on health and survival as 
does lifelong administration. we do not yet 
know if it will be possible to obtain the full 
protective effects by starting drug treatment 
in older animals. Fourth, it will be important to 
understand exactly how rapamycin increases 
lifespan. An obvious first step will be to deter-
mine how the drug alters downstream cellular 
processes, such as autophagy and translation, 
by determining if mutations that block these 
responses abrogate the effects of the drug. it 
will also be important to determine if TOR inhi-
bition by rapamycin has effects beyond those 
of other pathways that extend lifespan, such as 
reduced insulin/iGF signaling. This will start to 
reveal whether pharmacological inhibition of 
more than one target is needed to maximize 
health benefits during aging. Ultimately the 
aim is to translate this knowledge into inter-
ventions that can increase healthy lifespan 
in humans. excitingly, from this perspective, 
recent data from the Leiden longevity study 
suggests that individuals from long-lived fami-
lies have decreased expression of genes asso-
ciated with the mTOR pathway.12
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